TCTR20230622004Unknown不适用
The booster vaccination of the COVID-19 vaccine and its effect for preventing death in COVID-19 infected patients hospitalized in Si Sa Ket Hospital
/A0 个研究点目标入组 1,855 人开始时间: 2023年6月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 1,855
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •COVID-19 infected patients aged 18 years and older who were admitted to the hospital in Si Sa Ket province from January 1st, 2022 to December 31st, 2022.
排除标准
- •Discharge status from hospital was against advice or referral
研究者
相似试验
尚未招募
3 期
Intramuscular versus Subcutaneous COVID-19 needle length RCTCOVID-19Infection - Studies of infection and infectious agentsACTRN12624000294550Medical Research Institute of New Zealand (MRINZ)486
进行中（未招募）
1 期
sing one dose Pfizer to boost immunity after full vaccination with AstraZeneca in cancer patientsOnco-hematological patientsEUCTR2021-003573-58-BEAntwerp University Hospital182
已完成
3 期
Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patientsNL-OMON50602niversitair Medisch Centrum Groningen460
进行中（未招募）
1 期
Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patientsCOVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations is severely attenuated in kidney transplant patients compared to controls, especially when their immunosuppressive regimen contains mycophenolate mofetil (MMF) / mycophenolic acid (MPA).MedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865MedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 100000004865MedDRA version: 23.1Level: LLTClassification code 10084508Term: COVID-19 antibody testSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 100000004865MedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10084462Term: SARS-CoV-2 vaccinationSystem Organ Class: 100000004865MedDRA version: 23.0Level: LLTClassification code 10084463Term: SARS-CoV-2 immunisationSystem Organ Class: 100000004865MedDRA version: 23.0Level: LLTClassification code 10084466Term: SARS-CoV-2 immunizationSystem Organ Class: 100000004865MedDRA version: 23.1Level: PTClassification code 10084501Term: SARS-CoV-2 antibody testSystem Organ Class: 10022891 - InvestigationsEUCTR2021-004558-44-NLMCG460
已完成
4 期
SARS-CoV-2 antibody response after a booster dose of the mRNA COVID-19 vaccine (BNT162b2) among Thai children and adolescents aged 5-17 years.Healthy Thai children aged 5-17 years who received two doses of the mRNA vaccine (BNT162b2).children, Booster dose, Third vaccination, SARS-CoV-2, COVID-19, vaccines, mRNA vaccines, Adverse events, Vaccine safetyTCTR20230424002Siriraj Grant for Research Development150